Cargando…

Advanced subclinical atherosclerosis: A novel category within the cardiovascular risk continuum with distinct treatment implications

Traditionally, guidelines divide patients into primary and secondary prevention for atherosclerotic cardiovascular disease (ASCVD) risk management. However, the modern understanding of the biological progression of atherosclerosis is inconsistent with this binary approach. Therefore, a new approach...

Descripción completa

Detalles Bibliográficos
Autores principales: Blaha, Michael J., Abdelhamid, Magdy, Santilli, Francesca, Shi, Zhongwei, Sibbing, Dirk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826921/
https://www.ncbi.nlm.nih.gov/pubmed/36632617
http://dx.doi.org/10.1016/j.ajpc.2022.100456
_version_ 1784866963410911232
author Blaha, Michael J.
Abdelhamid, Magdy
Santilli, Francesca
Shi, Zhongwei
Sibbing, Dirk
author_facet Blaha, Michael J.
Abdelhamid, Magdy
Santilli, Francesca
Shi, Zhongwei
Sibbing, Dirk
author_sort Blaha, Michael J.
collection PubMed
description Traditionally, guidelines divide patients into primary and secondary prevention for atherosclerotic cardiovascular disease (ASCVD) risk management. However, the modern understanding of the biological progression of atherosclerosis is inconsistent with this binary approach. Therefore, a new approach demonstrating both atherosclerosis and ASCVD risk as a continuum is needed to give clinicians a framework for better matching risk and intensity of therapy. Advances in coronary imaging have most clearly brought this problem into view, as for example coronary artery calcium (CAC) scoring has shown that some individuals in the primary prevention have equal or higher ASCVD risk as certain subgroups in secondary prevention. This article introduces “advanced subclinical atherosclerosis” as a new and distinct clinical group that sits between the traditional groups of primary and secondary prevention. Importantly, this article also introduces a new graphic to visualize this intermediate population that is explicitly based on plaque burden. The aim of the graphic is both to educate and to allow for better identification of a patient's cardiovascular risk and guide more effective risk-based management.
format Online
Article
Text
id pubmed-9826921
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-98269212023-01-10 Advanced subclinical atherosclerosis: A novel category within the cardiovascular risk continuum with distinct treatment implications Blaha, Michael J. Abdelhamid, Magdy Santilli, Francesca Shi, Zhongwei Sibbing, Dirk Am J Prev Cardiol Commentary Traditionally, guidelines divide patients into primary and secondary prevention for atherosclerotic cardiovascular disease (ASCVD) risk management. However, the modern understanding of the biological progression of atherosclerosis is inconsistent with this binary approach. Therefore, a new approach demonstrating both atherosclerosis and ASCVD risk as a continuum is needed to give clinicians a framework for better matching risk and intensity of therapy. Advances in coronary imaging have most clearly brought this problem into view, as for example coronary artery calcium (CAC) scoring has shown that some individuals in the primary prevention have equal or higher ASCVD risk as certain subgroups in secondary prevention. This article introduces “advanced subclinical atherosclerosis” as a new and distinct clinical group that sits between the traditional groups of primary and secondary prevention. Importantly, this article also introduces a new graphic to visualize this intermediate population that is explicitly based on plaque burden. The aim of the graphic is both to educate and to allow for better identification of a patient's cardiovascular risk and guide more effective risk-based management. Elsevier 2022-12-24 /pmc/articles/PMC9826921/ /pubmed/36632617 http://dx.doi.org/10.1016/j.ajpc.2022.100456 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Commentary
Blaha, Michael J.
Abdelhamid, Magdy
Santilli, Francesca
Shi, Zhongwei
Sibbing, Dirk
Advanced subclinical atherosclerosis: A novel category within the cardiovascular risk continuum with distinct treatment implications
title Advanced subclinical atherosclerosis: A novel category within the cardiovascular risk continuum with distinct treatment implications
title_full Advanced subclinical atherosclerosis: A novel category within the cardiovascular risk continuum with distinct treatment implications
title_fullStr Advanced subclinical atherosclerosis: A novel category within the cardiovascular risk continuum with distinct treatment implications
title_full_unstemmed Advanced subclinical atherosclerosis: A novel category within the cardiovascular risk continuum with distinct treatment implications
title_short Advanced subclinical atherosclerosis: A novel category within the cardiovascular risk continuum with distinct treatment implications
title_sort advanced subclinical atherosclerosis: a novel category within the cardiovascular risk continuum with distinct treatment implications
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826921/
https://www.ncbi.nlm.nih.gov/pubmed/36632617
http://dx.doi.org/10.1016/j.ajpc.2022.100456
work_keys_str_mv AT blahamichaelj advancedsubclinicalatherosclerosisanovelcategorywithinthecardiovascularriskcontinuumwithdistincttreatmentimplications
AT abdelhamidmagdy advancedsubclinicalatherosclerosisanovelcategorywithinthecardiovascularriskcontinuumwithdistincttreatmentimplications
AT santillifrancesca advancedsubclinicalatherosclerosisanovelcategorywithinthecardiovascularriskcontinuumwithdistincttreatmentimplications
AT shizhongwei advancedsubclinicalatherosclerosisanovelcategorywithinthecardiovascularriskcontinuumwithdistincttreatmentimplications
AT sibbingdirk advancedsubclinicalatherosclerosisanovelcategorywithinthecardiovascularriskcontinuumwithdistincttreatmentimplications